Previous analysis has shown that cytolytic activity score (CYT; expression of Gzma and Prf1) is associated with increased survival benefit in cancer patients.61 We observed that, indeed, melanoma patients with higher CYT fared better, as did patients with higher expression of IFNγ-response genes (Figure S6C). The gene discussed is GZMA; the disease is cancer.